Side by side

1. 1.BPC-157 is proposed to act through VEGFR2 and nitric-oxide pathways in animal wound-healing models.
2. 2.TB-500, a fragment of thymosin beta-4, is studied for actin regulation and cell migration in animal models.
3. 3.The blend is sold on the idea that one drives blood-vessel formation and the other cell migration, so they complement each other.
4. 4.That complementarity is a sales narrative; no study has compared the combination with either peptide alone.
5. 5.Neither mechanism has been confirmed in controlled human studies.

• Tendon, muscle and ligament injury claims
• Gut-lining repair claims
• Post-surgical recovery claims
• All of these rest on animal models or anecdote rather than trials

• Reported faster recovery in user accounts
• Reduced pain claimed but never measured in a study
• Animal data show accelerated tissue closure for the individual peptides

• Injection-site pain and redness
• Headache, nausea and fatigue reported by users
• Compounds proposed to promote blood-vessel growth warrant caution in anyone with a cancer history
• No safety data for the combination

Research context only — no human protocol exists for the blend. Community schedules use roughly 250–500 micrograms of each peptide once daily, or the same total split morning and evening, for 6–12 weeks. Because the vial is fixed at a 1:1 ratio, adjusting one component changes the other, and syringe units depend entirely on how the vial was reconstituted.

Research context only